Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

As J&J Sees Continued Drug Price Declines, CEO Urges Slow Policy Change Via Trump's Blueprint

Jul 17 2018

• By Jessica Merrill

Related Content

Janssen Emphasizes Average Net Price Decline As Transparency Momentum Builds In States

Mar 12 2018

Pfizer Sets The Stage For A Biosimilar Showdown Over Exclusive Contracts

Sep 20 2017

Trump Drug Pricing Plan Includes Part D Surprises, Challenges PBM Business Model

May 12 2018

J&J Stays Within Price Pledge, But Average Doesn't Tell The Whole Story, Analyst Says

Mar 27 2018

FDA's Gottlieb: 'Pricing And Reimbursement Mischief' Holding Back Biosimilar Market

Mar 08 2018

Pfizer Agrees To Roll Back Prices On 40 Drugs, Yielding To Pressure From Trump

Jul 11 2018

Trump Tries To Shame A Defiant Pfizer On Drug Pricing

Jul 10 2018

J&J's Invokana Slows CKD Progression In Diabetes

Jul 17 2018

Related Companies

Johnson & Johnson

Pfizer Inc.

Merck & Co., Inc.

Additional Topics

Sales & Earnings Pricing Debate Commercial Biosimilars BioPharmaceutical

More from Earnings

More from Business

About Us

Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us

Customer Service
SubscribeOpens in new window
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window